Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop

References

• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7; 387(10031):1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4
   Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30; 387(10030):1837-46; PMID:26970723; http://dx.doi.org/10.1016/S0140-6736(16)00587-0
   Google Scholar
• Ebert PJ, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 2016; 44:609-21; PMID:26944201; http://dx.doi.org/10.1016/j.immuni.2016.01.024
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp, KL, Baas, P, Crin∫, L, Eberhardt, WE, Poddubskaya, E, Antonia, S, Pluzanski, A, Vokes, EE et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18:2039-47; PMID:22271879; http://dx.doi.org/10.1158/1078-0432.CCR-11-1823
   PubMed Web of Science ®Google Scholar
• Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013; 49:2968-71; PMID:23907003; http://dx.doi.org/10.1016/j.ejca.2013.07.001
   PubMed Web of Science ®Google Scholar
• Andrews S, Holden R. Characteristics and management of immune related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012; 4:299-307; PMID:23049279; http://dx.doi.org/10.2147/CMAR.S31873
   PubMedGoogle Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77; PMID:24332512; http://dx.doi.org/10.1016/S1470-2045(13)70551-5
   PubMed Web of Science ®Google Scholar
• Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995; 92:7976-80; PMID:7644523; http://dx.doi.org/10.1073/pnas.92.17.7976
   PubMed Web of Science ®Google Scholar
• Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71:1253-62; PMID:21216894; http://dx.doi.org/10.1158/0008-5472.CAN-10-2693
   PubMed Web of Science ®Google Scholar
• Cuende J, Lienart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P et al. Monoclonal antibodies against GARP/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med 2015; 7:284ra56; PMID:25904740; http://dx.doi.org/10.1126/scitranslmed.aaa1983
   PubMed Web of Science ®Google Scholar
• Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201:241-8; PMID:15657293; http://dx.doi.org/10.1084/jem.20041379
   PubMed Web of Science ®Google Scholar
• Lurquin C, Lethe B, De PE et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201:249-57; PMID:15657294; http://dx.doi.org/10.1084/jem.20041378
   PubMed Web of Science ®Google Scholar
• Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 2015; 16:e234-e245; PMID:25943068; http://dx.doi.org/10.1016/S1470-2045(15)70103-8
   PubMed Web of Science ®Google Scholar
• Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016 Mar 30. pii: blood-2015-12-686550. [Epub ahead of print]; PMID:27030389
   PubMedGoogle Scholar
• Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28:2367-2375; PMID:24732592; http://dx.doi.org/10.1038/leu.2014.137
   PubMed Web of Science ®Google Scholar
• Fest T, Cerhan JR, Gandhi MK et al. Validation of elevated blood soluble PD-L1 as an independent prognostic marker in newly diagnosed diffuse large B-cell lymphoma (D:BCL). Blood 2014;124:2998; published ahead of print December 4, 2014; http://dx.doi.org/10.1182/blood-2013-12-544197
   Google Scholar
• Labouré G, Parrens M-C, Tsaranazy A et al. Cell-of-origin (COO) classification, BCL2 and MYC expression associated-outcome in younger patients treated by RCHOP front-line therapy versus intensive regimen followed by autologous transplant for de novo advanced diffuse large B cell lymphoma (DBLCL): results of the French prospective multicentre randomized trial Goelams-075. Blood 2015; 126:3920; published ahead of print December 3, 2015
   Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1:32-42; PMID:24777248; http://dx.doi.org/10.1158/2326-6066.CIR-13-0013
   PubMed Web of Science ®Google Scholar
• Köhler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; http://dx.doi.org/10.1038/256495a0
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA 2015; 112:E966-972; PMID:25730880; http://dx.doi.org/10.1073/pnas.1500712112
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Kadin M. ASH Image Bank 2002; 2002:100484; http://dx.doi.org/10.1182/ashimagebank-2002-100484
   Google Scholar
• Küppers R. New insights in the biology of Hodgkin lymphoma. ASH Education Book 2012; 2012:328-34; PMID:23233600; http://dx.doi.org/ 10.1182/asheducation-2012.1.328
   Web of Science ®Google Scholar
• Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012; 18:1611-8; PMID:22271878; http://dx.doi.org/10.1158/1078-0432.CCR-11-1942
   PubMed Web of Science ®Google Scholar
• Armand P, Timmerman J, Lesokhin, A et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209-039). Presented at: 20th Congress of the European Hematology Association (EHA); Sunday, June 14, 2015; Vienna, Austria. Abstract #S808.
   Google Scholar
• Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 2016 Apr 11. pii: JCO664482. [Epub ahead of print]; PMID:27069084
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2013; 102:3871-9; PMID:12933571; http://dx.doi.org/10.1182/blood-2003-06-1841
   Web of Science ®Google Scholar
• Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106:1392-9; PMID:15870177; http://dx.doi.org/10.1182/blood-2004-12-4901
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig S, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268-77; PMID:20628145; http://dx.doi.org/10.1182/blood-2010-05-282780
   PubMed Web of Science ®Google Scholar
• Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014; 38:1715-23; PMID:25025450; http://dx.doi.org/10.1097/PAS.0000000000000297
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016; Feb 18; 127(7):869-81; PMID: 26702065; http://dx.doi.org10.1182/blood-2015-10-67323660
   Google Scholar
• Zinzani PL, Ribrag V, Moskowitz GH et al. Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL). Presented at: 57th Annual Meeting of the American Society of Hematology (ASH); Monday, December 7, 2015; Orlando, Florida, USA. Abstract #3986.
   Google Scholar
• Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19:3462-73; PMID:23674495; http://dx.doi.org/10.1158/1078-0432.CCR-13-0855
   PubMed Web of Science ®Google Scholar
• Pangault C, Amé-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, De Vos J, Roussel M, Monvoisin C, Lamy T et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 2010; 4:2080-9; PMID:22445383; http://dx.doi.org/10.1038/leu.2010.223
   PubMed Web of Science ®Google Scholar
• Amé-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, Jean R, Martin N, Marafioti T, Gaulard P, Lamy T et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 2012; 26:1053-63; PMID:22015774; http://dx.doi.org/10.1038/leu.2011.301
   PubMed Web of Science ®Google Scholar
• Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, Tarte K, Bastard C, Fest T. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 2012; 26:559-62; PMID:21941365; http://dx.doi.org/10.1038/leu.2011.266
   PubMed Web of Science ®Google Scholar
• Amé-Thomas P, Hoeller, S, Artchouni, C, Misiak, J, Braza, MS, Jean, R, Le Priol, J, Monvoisin, C, Martin, N, Gaulard, P et al. CD10 delineates a subset of human IL-4 producing follicular helperT cells involved in the survival of follicular lymphoma B cells. Blood 2015; 125:2381-5; PMID:25733581; http://dx.doi.org/10.1182/blood-2015-02-625152
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Barone F, Lucchesi D et al Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J Immunol 2012; 189:3767-76; PMID:22942425; http://dx.doi.org/10.4049/jimmunol.1201216
   PubMed Web of Science ®Google Scholar
• Amin R, Mourcin, F, Uhel, F, Pangault, C, Ruminy, P, Dupré, L, Guirriec, M, Marchand, T, Fest, T, Lamy, T et al. DC-SIGN–expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood 2015; 126:1911-20; PMID:26272216; http://dx.doi.org/10.1182/blood-2015-04-640912
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-32; PMID:21193697; http://dx.doi.org/10.1182/blood-2010-08-301945
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-75; PMID:22326955; http://dx.doi.org/10.1172/JCI61226
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124:2668-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014
   PubMed Web of Science ®Google Scholar
• Houot R, Kohrt HE, Marabelle A, Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol 2011; 32:510-6; PMID:21907000; http://dx.doi.org/10.1016/j.it.2011.07.003
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S et al. Pembrolizumab for ED SCLC: Efficacy and relationship with PD-L1 expression. Presented at: 16th World Conference on Lung Cancer; September 6–9th; Denver, CO. Abstract 3285.
   Google Scholar
• Houot R & Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009; 113:3546-52; PMID:18941113; http://dx.doi.org/10.1182/blood-2008-07-170274
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123:2355-7; PMID:23728169; http://dx.doi.org/10.1172/JCI69999
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK et al. In situ vaccination with a TLR9 agonist induces systemic Lymphoma Regression: A phase I/II study. J Clin Oncol 2010; 28:4324-32; PMID:20697067; http://dx.doi.org/10.1200/JCO.2010.28.9793
   PubMed Web of Science ®Google Scholar
• Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nature Immunol 2013; 14:1212-8; PMID:24240160; http://dx.doi.org/10.1038/ni.2762
   PubMed Web of Science ®Google Scholar
• Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR et al. Death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J Clin Oncol 2013; 31:4199-206; PMID:24127452; http://dx.doi.org/10.1200/JCO.2012.48.3685
   PubMed Web of Science ®Google Scholar
• Westin JR, Zhang M, Fayaf LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77; PMID:24332512; http://dx.doi.org/10.1016/S1470-2045(13)70551-5
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Ribra Vg, Michot J-M et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study (KEYNOTE-013). Presented at: 56th American Society of Hematology Annual Meeting. December 6–9, 2014, San Francisco, CA, USA. Abstract 290.
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P et al. Preliminary results of a Phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Presented at: 56th American Society of Hematology Annual Meeting. December 6–9, 2014, San Francisco, CA, USA. Abstract 291.
   Google Scholar
• Ansell SM. Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study. J Clin Oncol 2014; 32(Suppl. 5s):TPS8613.
   Google Scholar
• Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4371-7; PMID:19636010; http://dx.doi.org/10.1200/JCO.2008.21.3017
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang S, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015; 5:15179; PMID:26462617; http://dx.doi.org/10.1038/srep15179
   PubMed Web of Science ®Google Scholar
• Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105:3005-10; PMID:18287062; http://dx.doi.org/10.1073/pnas.0712237105
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-45; PMID:16778987; http://dx.doi.org/10.1172/JCI27745
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1:32-42; PMID:24777248; http://dx.doi.org/10.1158/2326-6066.CIR-13-0013
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32; PMID:11560997; http://dx.doi.org/10.1084/jem.194.6.823
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92:475-80; PMID:24732076; http://dx.doi.org/10.1038/icb.2014.26
   PubMed Web of Science ®Google Scholar
• Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010; 59:1367-77; PMID:20480365; http://dx.doi.org/10.1007/s00262-010-0866-5
   PubMed Web of Science ®Google Scholar
• Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci USA 2012; 109:6181-6; PMID:22474370; http://dx.doi.org/10.1073/pnas.1203954109
   PubMed Web of Science ®Google Scholar
• Pasero C, Speiser D, Derré L, Olive D. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol 2012; 12:478-85; PMID:22445654; http://dx.doi.org/10.1016/j.coph.2012.03.001
   PubMed Web of Science ®Google Scholar
• Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, Charbonnier A, Collette Y, Vey N, Olive D. Human Vg9Vd2 T cells specifically recognize and kill acute monocytic leukemic blasts. J Immunol 2012; 188:4701-8; PMID:22467661; http://dx.doi.org/10.4049/jimmunol.1103710
   PubMed Web of Science ®Google Scholar
• Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L, Olive D. The co-receptor BTLA negatively regulates human Vg9Vd2 T cell proliferation: a potential way of immune escape for lymphoma cells. Blood 2013; 122:922-31; PMID:23692853; http://dx.doi.org/10.1182/blood-2012-11-464685
   PubMed Web of Science ®Google Scholar
• Dahan R, Sega S, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 2015; 28:285-95; PMID:26373277; http://dx.doi.org/10.1016/j.ccell.2015.08.004
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells. Cancer Immunol Res 2015; 3:1148-57; PMID:26014098; http://dx.doi.org/10.1158/2326-6066.CIR-15-0059
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al. Safety and rumour responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
   PubMed Web of Science ®Google Scholar
• Yang X, Wang F, Zhang Y, Wang L, Antonenko S, Zhang S, Zhang YW, Tabrizifard M, Ermakov G, Wiswell D et al. Comprehensive analysis of the therapeutic IgG4 antibody pembrolizumab: hinge modification blocks half molecule exchange in vitro and in vivo. J Pharm Sci 2015; 104:4002-14; PMID:26308749; http://dx.doi.org/10.1002/jps.24620
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216
   PubMed Web of Science ®Google Scholar
• Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108:7142-7; PMID:21482773; http://dx.doi.org/10.1073/pnas.1016569108
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163-74; PMID:22570253; http://dx.doi.org/10.1158/0008-5472.CAN-12-0210
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520:373-7; PMID:25754329; http://dx.doi.org/10.1038/nature14292
   PubMed Web of Science ®Google Scholar